Citations

Mayo Clinic

Showing 10 of 108523 citations.

Optimizing Informed Decision Making for Basal Cell Carcinoma in Patients 85 Years or Older
Lee, Erica H. , Brewer, Jerry D., MacFarlane, Deborah F.

JAMA Dermatology | May 27, 2015 | Volume: 151 | Issue: 8 | Pages: 817

10.1001/jamadermatol.2015.1454 | PMID 26018032 Get It

Antibiofilm Activity of Low-Amperage Continuous and Intermittent Direct Electrical Current
Schmidt-Malan, Suzannah M., Karau, Melissa J. , Cede, Julia , Greenwood‐Quaintance, Kerryl E. , Brinkman, Cassandra L., Mandrekar, Jayawant N. , Patel, Robin , Patel, Robin

Antimicrobial Agents and Chemotherapy | May 27, 2015 | Volume: 59 | Issue: 8 | Pages: 4610-4615

10.1128/aac.00483-15 | PMID 26014944 Get It

ABSTRACT Bacterial biofilms are difficult to treat using available antimicrobial agents, so new antibiofilm strategies are needed. We previously showed that 20, 200, and 2,000 μA of electrical current reduced bacterial biofilms of Staphylococcus aureus , Staphylococcus epidermidis , and Pseudomonas aeruginosa . Here, we tested continuous direct current at lower amperages, intermittent direct current, and combinations of surface materials (Teflon or titanium) and electrode compositions (stainless steel, graphite, titanium, or platinum) against S. aureus , S. epidermidis , and P. aeruginosa biofilms. In addition, we tested 200 or 2,000 μA for 1 and 4 days against biofilms of 33 strains representing 13 species of microorganisms. The logarithmic reduction factor was used to measure treatment effects. Using continuous current delivery, the lowest active amperage was 2 μA for 1, 4, or 7 days against P. aeruginosa and 5 μA for 7 days against S. epidermidis and S. aureus biofilms. Delivery of 200 μA for 4 h a day over 4 days reduced P. aeruginosa , S. aureus , and S. epidermidis biofilms on Teflon or titanium discs. A reduction of P. aeruginosa , S. aureus , and S. epidermidis biofilms was measured for 23 of 24 combinations of surface materials and electrode compositions tested. Four days of direct current delivery reduced biofilms of 25 of 33 strains studied. In conclusion, low-amperage current or 4 h a day of intermittent current delivered using a variety of electrode compositions reduced P. aeruginosa , S. aureus , and S. epidermidis biofilms on a variety of surface materials. The electricidal effect was observed against a majority of bacterial species studied.
Cardiopoietic Index Predicts Heart Repair Fitness of Patient-Derived Stem Cells
Crespo‐Diaz, Ruben , Pérez-Terzic, Carmen, Waele, P. De, Mauën, Sébastien, Behfar, Atta , Yamada, Satsuki , Bartúnek, Jozef , Terzic, André , Behfar, Atta

Biomarkers in Medicine | May 27, 2015 | Volume: 9 | Issue: 7 | Pages: 639-649

10.2217/bmm.15.31 | PMID 26014833 Get It

BRCA2‐associated pancreatic cancer and current screening guidelines
Kasi, Pashtoon Murtaza , Pedersen, Katrina S. , McWilliams, Robert R. , Kasi, Pashtoon Murtaza , Pedersen, Katrina

Cancer | May 27, 2015 | Volume: 121 | Issue: 17 | Pages: 3046-3046

10.1002/cncr.29447 | PMID 26018189 Get It

High-resolution mapping of architectural DNA binding protein facilitation of a DNA repression loop in Escherichia coli
Becker, Nicole A. , Maher, L. James

Proceedings of the National Academy of Sciences | May 27, 2015 | Volume: 112 | Issue: 23 | Pages: 7177-7182

10.1073/pnas.1500412112 | PMID 26039992 Get It

Significance Double-stranded DNA is one of the stiffest polymers in biology, resisting both bending and twisting over hundreds of base pairs. However, tightly bent DNA loops are formed by proteins that turn off (repress) genes in bacteria. It has been shown that “architectural” proteins capable of kinking any DNA molecule without sequence preference facilitate this kind of gene repression. The mechanism of this effect is unknown for DNA loops involving the well-known Escherichia coli lac repressor. Here we adapt high-resolution protein-mapping techniques to show that an architectural protein directly binds tightly looped DNA to facilitate gene repression by the lac repressor.
A case of catastrophic antiphospholipid syndrome: first report with advanced cardiac imaging using MRI
Rosenbaum, Andrew , Anavekar, Nandan S., Ernste, Floranne C. , Mankad, Sunil , Le, Rachel J., Manocha, Kevin K. , Barsness, Gregory W.

Lupus | May 27, 2015 | Volume: 24 | Issue: 12 | Pages: 1338-1341

10.1177/0961203315587960 | PMID 26014099 Get It

This present case pertains to a 48-year-old woman with a history of antiphospholipid syndrome, who presented with progressive fatigue, generalized weakness, and orthopnea acutely. She had a prior diagnosis of antiphospholipid syndrome with recurrent deep vein thromboses (DVTs) and repeated demonstration of lupus anticoagulants. She presented in cardiogenic shock with markedly elevated troponin and global myocardial dysfunction on echocardiography, and cardiac catheterization revealed minimal disease. Cardiac magnetic resonance imaging was performed, which revealed findings of perfusion defects and microvascular obstruction, consistent with the pathophysiology of catastrophic antiphospholipid syndrome (CAPS). Diagnosis was made based on supportive imaging, including head magnetic resonance imaging (MRI) revealing multifocal, acute strokes; microvascular thrombosis in the dermis; and subacute renal infarctions. The patient was anticoagulated with intravenous unfractionated heparin and received high-dose methylprednisolone, plasmapheresis, intravenous immunoglobulin, and one dose each of rituximab and cyclophosphamide. She convalesced with eventual myocardial recovery after a complicated course. The diagnosis of CAPS relies on the presence of (1) antiphospholipid antibodies and (2) involvement of multiple organs in a microangiopathic thrombotic process with a close temporal association. The myocardium is frequently affected, and heart failure, either as the presenting symptom or cause of death, is common. Despite echocardiographic evidence of myocardial dysfunction in such patients, MRIs of CAPS have not previously been reported. This case highlights the utility in assessing the involvement of the myocardium by the microangiopathic process with MRI. Because the diagnosis of CAPS requires involvement in multiple organ systems, cardiac MRI is likely an underused tool that not only reaffirms the pathophysiology of CAPS, but could also clue clinicians in to the possibility of a diffuse thrombotic process.
Multi-Institutional Validation of an OSATS for the Assessment of Cystoscopic and Ureteroscopic Skills
Argun, Ömer Burak , Chrouser, Kristin , Chauhan, Sanket, Monga, Manoj, Knudsen, Bodo E. , Box, Geoffrey N., Lee, David I. , Gettman, Matthew T., Poniatowski, Lauren H. , Wang, Qi , Reihsen, Troy, Sweet, Robert

Journal of Urology | May 27, 2015 | Volume: 194 | Issue: 4 | Pages: 1098-1106

10.1016/j.juro.2015.02.2959 | PMID 26025502 Get It

Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression
Kelm, Zachary S. , Korfiatis, Panagiotis , Lingineni, Ravi K., Daniels, John R., Buckner, Jan C. , Parney, Ian F. , Carter, Rickey E. , Korfiatis, Panagiotis D, Lachance, Daniel Honore , Erickson, Bradley J. , Parney, Ian F , Carter, Rickey E

Journal of Medical Imaging | May 26, 2015 | Volume: 2 | Issue: 2 | Pages: 026001

10.1117/1.jmi.2.2.026001 | PMID 26158114 Get It

Novel Agents in the Therapy of Hodgkin Lymphoma
Ansell, Stephen M.

American Society of Clinical Oncology Educational Book | May 26, 2015 | Volume: No volume available | Issue: 35 | Pages: e479-e482

10.14694/edbook_am.2015.35.e479 | PMID 25993212 Get It

Hodgkin lymphoma (HL) is a B-cell malignancy that typically has a favorable prognosis when treated with chemotherapy, often in combination with radiation therapy. The prognosis for patients whose disease relapses or is refractory, however, is far less favorable and novel therapies are needed for these patients. The unique cellular composition of HL provides a number of opportunities to target either the malignant Reed-Sternberg cell or the inflammatory tumor microenvironment. Antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints, have all demonstrated activity in HL. Current and future trials are exploring the use of these agents in combination with each other and with standard chemotherapy.